We may thus hypothesize that the PD-L1 checkpoint molecule could represent a viable target for immunotherapy especially in MHC-II-positive oral cancer, even though further experiments are required to confirm this association. The gene discussed is CD274; the disease is lip and oral cavity carcinoma.